Calgary, Alberta – TheNewswire – October 14, 2020 – (CNSX:MXT.CN) Jim Durward states: “On September 8, 2020, Infection Control Today published an article by Kevin Kavanagh, MD in which Dr. Kavanagh states:
“Several recent studies have supported the growing hypothesis that coronavirus disease 2019 (COVID-19) is primarily a cardiovascular, and not a pulmonary virus. The narrative that those affected are usually asymptomatic and have very mild or no disease may be false. Many of those who are asymptomatic may actually fall victim to myocarditis, a sinister, stealth-like disease, whose resulting disability may take decades to manifest. Concerns for cardiovascular involvement of SARS-CoV-2 have been present since the early genesis of the pandemic. A research paper from China found that 20% of COVID-19 hospitalized patients developed heart disease and thromboembolic events happened in 31% of those in the ICU. Another from Germany reported ongoing myocardial inflammation in 60% of 100 recently recovered patients with COVID-19.””
Furthermore, according to the British Journal of Pharmacology, as published by the US National Library of Medicine, National Institutes for Health:
“Cannabidiol (CBD) has beneficial effects in disorders as wide ranging as diabetes, Huntington’s disease, cancer and colitis. Accumulating evidence now also suggests that CBD is beneficial in the cardiovascular system. CBD has direct actions on isolated arteries, causing both acute and time-dependent vasorelaxation. In vitro incubation with CBD enhances the vasorelaxant responses in animal models of impaired endothelium-dependent vasorelaxation. CBD protects against the vascular damage caused by a high glucose environment, inflammation or the induction of type 2 diabetes in animal models and reduces the vascular hyperpermeability associated with such environments. A common theme throughout these studies is the anti-inflammatory and anti-oxidant effect of CBD. In the heart, in vivo CBD treatment protects against ischaemia-reperfusion damage and against cardiomyopathy associated with diabetes. Similarly, in a different model of ischaemia-reperfusion, CBD has been shown to reduce infarct size and increase blood flow in animal models of stroke, sensitive to 5HT1A receptor antagonism.”
The paper concludes with “In summary, this review has presented evidence of the positive effects of CBD in the cardiovascular system, …(edited for brevity). In vivo, CBD treatment does not appear to have any effect on resting blood pressure or heart rate, but does reduce the cardiovascular response to various types of stress. In vivo, CBD treatment has a protective role in reducing the effects of cardiac ischaemia and reperfusion, or in reducing cardiac dysfunction associated with diabetes. Similarly, CBD has a protective role in reducing the ischaemic damage in models of stroke, partly due to maintaining cerebral blood flow. In models of altered vascular permeability, CBD reduces the hyperpermeability of the BRB in diabetes and BBB hyperpermeability after LPS injection. Similarly, CBD ameliorates the negative effects of a high glucose environment on cell adhesion molecules and barrier function. Together, these data suggest that the cardiovascular system is indeed a valid therapeutic target for CBD. “
Jim Durward further states: “Since inception, MXT has focused on the small-scale medical cannabis grower and has specifically designed extraction machines to address this market horizontal. Often our customers report that one of the reasons they prefer to grow their own is that they cannot afford “big-pharma” prescription medications. The Covid-19 pandemic has added another potential layer of complexity for those self-medicators who have co-morbidities and the search is on to determine if cannabis compounds can provide positive effects. Recently our new Essential extraction system was used to successfully extract CBD from hemp – here are the HPLC-based test results:
Our CO2-based extractors can provide even higher levels of concentration. Using our extractors, craft growers can generate high-potency, full-spectrum CBD concentrates in-house, thereby accessing the potential benefits without being forced to purchase CBD through corporate channels or the black market.”
The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
ABOUT MEDXTRACTOR CORP:
The Corporation is a Calgary-based company that manufactures craft-scale bio-extractors that can be used to extract compounds from a variety of botanical materials. The Corporation manufactures both CO2-based and alcohol-based machines. Growing demand is from the premium craft medical cannabis market as these growers respond to the shift toward high-purity oils and concentrates. The Corporation may also develop related products as demand becomes apparent. The Corporation has installations in multiple countries worldwide and owns the US and Canadian patents on its CO2-based extraction process.
FOR FURTHER INFORMATION, PLEASE CONTACT:
James M. Durward, President and CEO
Telephone: (403) 689-3901
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.